StockData
NYMXFOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

NYMOX PHARMACEUTICAL CORP

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Sep 14, 2026
$0.04+0.00 (0.00%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

NYMOX PHARMACEUTICAL CORP revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Nymox Pharmaceutical does not break out revenue by segment, region or product in the tagged data of its filings for this period type.